Valneva's IXCHIQ® Vaccine Response
In recent developments, Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a pioneering specialty vaccine company, has stepped forward to address the significant chikungunya outbreak escalating in La Réunion. With the collaboration and backing of the local public health authorities, Valneva has committed to supplying 40,000 doses of its IXCHIQ® vaccine starting in early April, with the potential for further supply through local wholesalers. This initiative aligns with the guidance of France's national public health agency, specifically targeting adults aged 65 and over who are at increased risk due to underlying health conditions.
The Chikungunya Outbreak in La Réunion
Recent reports indicate that the chikungunya outbreak in La Réunion has intensified dramatically, with approximately 8,600 cases documented since the beginning of the year. A staggering number of nearly 3,000 new cases were registered within just one week in early March. This upsurge resembles the intensive outbreak that occurred in 2005-2006, raising concerns about the potential spread of the virus beyond the island to mainland France and other territories.
Emergency Measures in Response to the Outbreak
In response to this health crisis, local authorities in La Réunion have enacted a Level 4 emergency management plan aiming to contain the outbreak effectively. In parallel, the CDC has issued travel alerts to protect international travelers as millions visit France's popular destinations annually. The importance of vaccination as a preventive measure cannot be overstated, as highlighted by Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, who emphasizes the urgent need to vaccinate as many individuals as possible.
Unmatched Vaccine for a Pressing Medical Need
IXCHIQ® holds the distinction of being the world’s first licensed chikungunya vaccine, a critical tool designed to meet a significant unmet medical need. This vaccine has received approval across multiple regions, including the United States, Europe, Canada, and the United Kingdom, specifically for individuals 18 years and older. Moreover, recent advancements are paving the way for a potential label extension to include adolescents aged 12 and older.
Vaccine Access and Global Partnerships
Valneva is actively working on enhancing the accessibility of IXCHIQ® in various regions. In an effort to broaden vaccine availability, Valneva expanded its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), secured a $41.3 million grant to promote vaccine access in low- and middle-income countries (LMICs). This ambitious goal involves post-marketing studies and research aimed at potential label extensions to support vaccination in children, adolescents, and pregnant women.
Highlights of Valneva's Collaborative Efforts
The strategic partnership with the Serum Institute of India, the world's largest vaccine manufacturer by doses, underscores Valneva's commitment to making IXCHIQ® accessible across Asia at affordable rates. Notably, this agreement complements a previous partnership Valneva forged with Instituto Butantan in Brazil to advance chikungunya vaccine development and availability in Latin American countries.
Understanding Chikungunya
The chikungunya virus is primarily transmitted through the bites of infected Aedes mosquitoes, causing symptoms such as fever and severe joint pain that can adversely affect individuals for extended periods. The resurgence of chikungunya since 2004 has led to widespread outbreaks globally, impacting over 110 countries. The World Health Organization (WHO) recognizes chikungunya as a significant public health concern, particularly as climate change facilitates the geographical spread of mosquito vectors.
Valneva's Commitment to Innovation
Valneva is dedicated to developing, manufacturing, and marketing prophylactic vaccines that address public health challenges. With a focused approach on unmet medical needs, Valneva has successfully advanced several vaccines from early research and development to humanitarian aid. Currently, the company offers three exclusive travel vaccines, including IXCHIQ®, while actively working on candidates targeting Lyme disease, Zika virus, and more.
Connecting with Valneva
For investor inquiries, Valneva provides contact information for their leaders in communication and investor relations. Laetitia Bachelot-Fontaine serves as the VP of Global Communications & European Investor Relations and can be reached at +33 (0)6 4516 7099, while Joshua Drumm, Ph.D., holds the position of VP of Global Investor Relations, available at +001 917 815 4520.
Frequently Asked Questions
1. What is the IXCHIQ® vaccine?
IXCHIQ® is the world’s first licensed vaccine for chikungunya, providing protection against the disease caused by the chikungunya virus.
2. Why is there a chikungunya outbreak in La Réunion?
The outbreak is due to an increase in chikungunya virus transmission, amplified by the region's mosquito population and weather conditions.
3. Who is prioritized for vaccination with IXCHIQ®?
Vaccination is prioritized for adults aged 65 and older, especially those with existing health conditions, as well as healthcare workers.
4. How is Valneva addressing vaccine accessibility?
Valneva has partnered with CEPI and the Serum Institute of India to enhance vaccine accessibility in LMICs and promote affordable pricing.
5. What symptoms are associated with chikungunya?
Chikungunya symptoms include fever, joint pain, headache, nausea, fatigue, and rash; joint pain can persist for weeks or months.
